With highly specialized testing technologies—including next-generation sequencing (NGS), polymerase chain reaction (PCR), immunohistochemistry (IHC), and fluorescence in situ hybridization (FISH)—we can help you get answers you can trust so you can make more informed decisions for patient care.
Comprehensive Genomic Profiling Pan-Cancer Panels
Our comprehensive, guideline-driven panels deliver insights to help you make treatment decisions based on the mutations found in the individual’s tumor sample. These panels can be helpful in determining eligibility in clinical studies.
The Solid Tumor Expanded Panel provides a comprehensive molecular profile that includes 500+ genes associated with a broad spectrum of cancers. This panel can be used for a comprehensive analysis of a patient’s genetic profile and contains clinically actionable genes as well as emerging genes.
The Solid Tumor Core Panel includes 49 genes and is designed to support physicians in choosing the most appropriate therapies for their patients based on the alterations found in the tumor sample DNA.
The Solid Tumor Expanded Panel provides a comprehensive molecular profile that includes 500+ genes associated with a broad spectrum of cancers. This panel can be used for a comprehensive analysis of a patient’s genetic profile and contains clinically actionable genes as well as emerging genes.
The Solid Tumor Core Panel includes 49 genes and is designed to support physicians in choosing the most appropriate therapies for their patients based on the alterations found in the tumor sample DNA.
